7/18/2011 7:23:44 AM
Two months after announcing acquisition of US-based Cephalon, drug maker's personnel expected to pay price. Teva informs its branded products senior management that they won't remain with company. Cephalon may become branded products division, activity may be relocated from Israel to US. Teva: Various alternatives weighed. Will Teva's imminent reorganization campaign lead to a layoff round of its Israel staff? In a move initiated a year ago, Teva Pharmaceutical Industries announced organizational changes and the parachuting of directorate member Professor Yitzhak Peterburg into the position of VP Global Branded Products – Teva's proprietary research and development products division.
comments powered by